<DOC>
	<DOCNO>NCT01683110</DOCNO>
	<brief_summary>The objective study provide access cabozantinib eligible subject medullary thyroid cancer ( MTC ) pending approval Exelixis ' New Drug Application ( NDA ) FDA commercial availability cabozantinib .</brief_summary>
	<brief_title>Expanded Access Cabozantinib Medullary Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>The subject histologically confirm diagnosis MTC unresectable , locally advanced , metastatic The subject document progressive disease ( PD ) determine investigator The subject previously treat available standard therapy unresectable , locally advanced , metastatic MTC ; currently available therapy consider inappropriate subject determine investigator The subject Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 The subject adequate organ marrow function The subject capable understanding comply protocol requirement sign informed consent document Sexually active subject ( men woman ) must agree use medically accept barrier method contraception ( eg , male female condom ) course study 3 month last dose cabozantinib receive part study , even oral contraceptive also use . All subject reproductive potential must agree use barrier method second method birth control . The subject receive cytotoxic chemotherapy ( include investigational cytotoxic chemotherapy ) biologic agent ( eg , antibody ) within 4 week , nitrosoureas/mitomycin C within 6 week first dose cabozantinib The subject previously enrol clinical trial evaluate cabozantinib include placebocontrolled trial subject may treat cabozantinib The subject receive radiation therapy : 1. thoracic cavity , abdomen , pelvis within 12 week first dose study treatment , ongoing complication without complete recovery heal prior radiation therapy 2. bone brain metastasis within 14 day first dose cabozantinib 3. site ( ) within 28 day first dose cabozantinib The subject receive radionuclide treatment within 6 week first dose cabozantinib The subject receive prior treatment small molecule kinase inhibitor hormonal therapy ( include investigational kinase inhibitor hormone ) within 14 day five halflifes compound active metabolite , whichever longer , first dose cabozantinib The subject receive type investigational agent within 28 day first dose cabozantinib The subject recover baseline CTCAE ≤ Grade 1 toxicity due prior therapy except alopecia clinically nonsignificant side effect The subject active brain metastasis epidural disease ( certain exception apply ) The subject require chronic concomitant treatment strong CYP3A4 inducer ( eg , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's Wort ) The subject require concomitant treatment , therapeutic dos , anticoagulant warfarin warfarinrelated agent , heparin , thrombin Factor Xa inhibitor , antiplatelet agent ( eg , clopidogrel ) . Low dose aspirin ( ≤ 81 mg/day ) , lowdose warfarin ( ≤ 1 mg/day ) , prophylactic low molecular weight heparin permit The subject experience following : 1. clinicallysignificant GI bleeding within 6 month first dose cabozantinib 2. hemoptysis &gt; 0.5 teaspoon ( 2.5 ml ) red blood within 3 month first dose cabozantinib 3. sign indicative pulmonary hemorrhage within 3 month first dose cabozantinib The subject radiographic evidence cavitating pulmonary lesion ( ) The subject radiographic evidence tumor contact , invade encase major blood vessel The subject evidence tumor invade GI tract ( esophagus , stomach , small large bowel , rectum anus ) , evidence endotracheal endobronchial tumor within 28 day first dose cabozantinib The subject uncontrolled , significant intercurrent recent illness ( may include certain cardiac disorder , certain gastrointestinal disorder , major surgery ) The subject unable swallow capsule The subject pregnant breastfeed The subject unable unwilling abide study protocol cooperate fully investigator designee The subject another diagnosis malignancy , require systemic treatment , within two year first dose cabozantinib , unless malignancy treat curative intent subject take anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>